Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...
Hurricane Helene's massive rains and flooding is a major health and safety risk for residents exposed to potential ...
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for ...
The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...
The global chronic disease management market size is estimated to be worth USD 5.57 billion in 2024 and is projected to reach ...
In adults with undiagnosed respiratory symptoms, dyspnea impact was worse in those with PRISm vs undiagnosed asthma or COPD.
The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.
Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...
The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...
The following is a summary of “Comparative Effectiveness of qSOFA, CURB-65, and PSI in Predicting Pneumonia Hospitalization ...
Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase three and phosphodiesterase 4 (“PDE3 and PDE4”) that combines bronchodilator and non-steroidal ...
Researchers mapped the biological influences on 4,775 plasma proteins, revealing the interplay of modifiable and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback